WO2011138265A2 - Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine - Google Patents

Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine Download PDF

Info

Publication number
WO2011138265A2
WO2011138265A2 PCT/EP2011/056938 EP2011056938W WO2011138265A2 WO 2011138265 A2 WO2011138265 A2 WO 2011138265A2 EP 2011056938 W EP2011056938 W EP 2011056938W WO 2011138265 A2 WO2011138265 A2 WO 2011138265A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
acetamide
sulfonyl
indo
phenylmethyl
Prior art date
Application number
PCT/EP2011/056938
Other languages
English (en)
Other versions
WO2011138265A3 (fr
Inventor
Jonathan Mark Bentley
Tara Davenport
Mark Slack
Original Assignee
Evotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Ag filed Critical Evotec Ag
Publication of WO2011138265A2 publication Critical patent/WO2011138265A2/fr
Publication of WO2011138265A3 publication Critical patent/WO2011138265A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Abstract

L'invention concerne des composés de la formule (I) dans laquelle A, R1à R8 ont la signification mentionnée dans le descriptif et les revendications. Ces composés sont utiles comme antagonistes du récepteur de l'orexine. L'invention concerne également des compositions pharmaceutiques, la préparation de ces composés, ainsi que leur production et leur utilisation comme médicament.
PCT/EP2011/056938 2010-05-03 2011-05-02 Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine WO2011138265A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161735 2010-05-03
EP10161735.5 2010-05-03

Publications (2)

Publication Number Publication Date
WO2011138265A2 true WO2011138265A2 (fr) 2011-11-10
WO2011138265A3 WO2011138265A3 (fr) 2015-06-25

Family

ID=42732252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/056938 WO2011138265A2 (fr) 2010-05-03 2011-05-02 Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine

Country Status (1)

Country Link
WO (1) WO2011138265A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014188248A1 (fr) 2013-05-22 2014-11-27 Laboratorio Chimico Internazionale S.P.A. Procédé de préparation d'ivabradine
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US9499517B2 (en) 2012-02-07 2016-11-22 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US9556130B2 (en) 2014-11-20 2017-01-31 Takeda Pharmaceutical Company Limited 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
US10894789B2 (en) 2016-02-12 2021-01-19 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
WO2022119864A1 (fr) * 2020-12-01 2022-06-09 Purdue Research Foundation Composés pour le traitement du sars

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047577A1 (fr) 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de phenyluree et de phenylthiouree utilises comme antagonistes des recepteurs de l'orexine
WO2000047576A1 (fr) 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de cinnamide utilises en tant qu'antagonistes des recepteurs de l'orexine-1
WO2001068609A1 (fr) 2000-03-14 2001-09-20 Actelion Pharmaceuticals Ltd. Derives de 1,2,3,4-tetrahydroisoquinoline
WO2001096302A1 (fr) 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines utiles en tant qu'antagonistes du recepteur d'orexine
WO2002089800A2 (fr) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. Derives d'amines cycliques n-aroyl utilises comme antagonistes du recepteur d'orexine
WO2004004733A1 (fr) 2002-07-09 2004-01-15 Actelion Pharmaceuticals Ltd. Derives de 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido et 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone
WO2008020405A2 (fr) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Composés d'azétidine
EP2161266A1 (fr) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Dérivés de benzofurane en tant qu'antagonistes du récepteur de l'orexine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9902455D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
US20070232681A1 (en) * 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
CA2716332A1 (fr) * 2008-02-22 2009-08-27 Irm Llc Composes et compositions comme modulateurs d'activite de gpr119

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047577A1 (fr) 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de phenyluree et de phenylthiouree utilises comme antagonistes des recepteurs de l'orexine
WO2000047576A1 (fr) 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de cinnamide utilises en tant qu'antagonistes des recepteurs de l'orexine-1
WO2001068609A1 (fr) 2000-03-14 2001-09-20 Actelion Pharmaceuticals Ltd. Derives de 1,2,3,4-tetrahydroisoquinoline
WO2001096302A1 (fr) 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines utiles en tant qu'antagonistes du recepteur d'orexine
WO2002089800A2 (fr) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. Derives d'amines cycliques n-aroyl utilises comme antagonistes du recepteur d'orexine
WO2004004733A1 (fr) 2002-07-09 2004-01-15 Actelion Pharmaceuticals Ltd. Derives de 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido et 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone
WO2008020405A2 (fr) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Composés d'azétidine
EP2161266A1 (fr) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Dérivés de benzofurane en tant qu'antagonistes du récepteur de l'orexine

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ADAMANTIDIS A.R. ET AL., NATURE, 2007, pages 420 - 425
CHEMELLI R.M. ET AL., CELL, vol. 98, 1999, pages 437 - 451
DE LECEA L. ET AL., PNAS, vol. 95, 1998, pages 322 - 27
ISHII Y. ET AL., BEHAV.BRAIN.RES., vol. 157, 2005, pages 331 - 341
MIDEA M. ET AL., PNAS, vol. 101, no. 13, 2004, pages 4649 - 4654
SAKURAI ET AL., CELL, vol. 92, 1998, pages 573 - 585
SAKURAI T. ET AL., CELL, vol. 92, 1998, pages 573 - 585
SAKURAI T., NATURE REVIEWS NEUROSCIENCE, vol. 8, 2007, pages 171 - 181
SMITH M.I. ET AL., NEUROSCI. LETTERS, 2003, pages 256 - 258
THORPE A.J. ET AL., BRAIN RES., vol. 1050, 2005, pages 156 - 162

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9896452B2 (en) 2012-02-07 2018-02-20 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US9499517B2 (en) 2012-02-07 2016-11-22 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
WO2014188248A1 (fr) 2013-05-22 2014-11-27 Laboratorio Chimico Internazionale S.P.A. Procédé de préparation d'ivabradine
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
US10159677B2 (en) 2014-11-20 2018-12-25 Takeda Pharmaceutical Company Limited 4-OXO-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
US9770450B2 (en) 2014-11-20 2017-09-26 Takeda Pharmaceutical Company Limited 4-OXO-3,4-dihydro-1,2,3-benzotriazine as modulators of GPR139
US9556130B2 (en) 2014-11-20 2017-01-31 Takeda Pharmaceutical Company Limited 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
US10561662B2 (en) 2014-11-20 2020-02-18 Takeda Pharmaceutical Company Limited 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
US11173161B2 (en) 2014-11-20 2021-11-16 Takeda Pharmaceutical Company Limited 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
US10894789B2 (en) 2016-02-12 2021-01-19 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
US11434236B2 (en) 2016-02-12 2022-09-06 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
WO2022119864A1 (fr) * 2020-12-01 2022-06-09 Purdue Research Foundation Composés pour le traitement du sars

Also Published As

Publication number Publication date
WO2011138265A3 (fr) 2015-06-25

Similar Documents

Publication Publication Date Title
WO2011138265A2 (fr) Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine
CN110719902B (zh) Ssao抑制剂
JP4426660B2 (ja) ピラゾール誘導体、その製法および医薬としてのその使用
TWI491595B (zh) 作為香草類化合物受體之配體之經取代苯基尿素及苯基醯胺
KR0175310B1 (ko) N-치환 복소환식 유도체, 그의 제조방법 및 그를 함유하는 약학 조성물
CN110003123B (zh) 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂
AU2006320621A1 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
WO2006024779A1 (fr) Derives de sulfonamides, leur preparation et leur application en therapeutique
EP2161266A1 (fr) Dérivés de benzofurane en tant qu'antagonistes du récepteur de l'orexine
CN1298386A (zh) 在肥胖症和其它病症的治疗中用作神经肽yy5受体配体的n－取代的氨基1,2,3,4－四氢化萘
WO2011138266A1 (fr) Dérivés d'indolizine et d'imidazopyridine comme antagonistes de récepteurs d'orexine
NO310071B1 (no) 1-Fenyl-3-pyrazolkarboksamider som virker på neurotensin- reseptorer, mellomprodukter for fremstilling av dem og farmasöytiske preparater inneholdende dem
LV11028B (en) Novel benzimidazole and azabenzimidazole derivatives
SK283463B6 (sk) Indolínové deriváty, spôsob ich prípravy, medziprodukty tohto spôsobu a farmaceutický prostriedok obsahujúci tieto deriváty
JP2005517681A (ja) ５−ｈｔ２ｃ受容体と関連する疾患における使用のための４−スルフィド／スルホキシド／スルホニル−１ｈ−ピラゾリル誘導体化合物
AU2008320718B2 (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
JP6250674B2 (ja) Ｎ型カルシウムチャネル遮断剤としてのピロロピラゾール
WO2004013100A2 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EP2297135B1 (fr) Procédé de préparation d'un antagoniste des récepteurs de l'orexine
Mésangeau et al. Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT1 melatoninergic ligands
JP2013534229A (ja) バニロイド受容体リガンドとしての置換された環状カルボキサミド誘導体および尿素誘導体
KR20180030582A (ko) Cgrp 수용체 길항제
WO2015124764A1 (fr) Procédé de synthèse de dabigatran étexilate mésylate, intermédiaires de ce procédé et nouveau polymorphe de dabigatran étexilate
CN1101815C (zh) 3－酰氨基苯并二氢吡喃磺酰基(硫)脲，其制备方法和用途及含其的药物制剂
CA2720275A1 (fr) Compose d'indolinone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11718036

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 04.02.2013

122 Ep: pct application non-entry in european phase

Ref document number: 11718036

Country of ref document: EP

Kind code of ref document: A2